Global Dry Age-Related Macular DegenerationMarket
The global Dry Age-Related Macular Degeneration market is estimated to be worth over USD20.9 Bn in 2033 and is expected to grow at CAGR of8.2% during the forecast period (2024-2033). The global market for dry age-related macular degeneration (AMD) is marked by a complicated interplay of driving factors, notable developments, and innovative technologies aimed at addressing the unmet medical needs of patients affected by this debilitating eye disease. One of the primary driving factors is the diversifying elderly population across the world, as old age is a primary risk factor for the development of dry AMD. With the demographic shift towards older age groups, the incidence of dry AMD is on the surge, fueling demand for effective treatments and management strategies.
Significant developments in the market comprise advancements in retinal imaging technologies, such as optical coherence tomography (OCT) and fundus autofluorescence (FAF), which facilitate early detection, precise diagnosis, and monitoring of dry AMD progression. In addition to that, there is growing interest in the development of novel therapeutic approaches targeting different pathways implicated in AMD pathogenesis, including inflammation, oxidative stress, and retinal degeneration. Pharmaceutical companies are actively engaged in research and development efforts to determine promising drug candidates, with several pipeline drugs in clinical trials offering hope for improved treatment alternatives in the future.
Along with that, the integration of digital health solutions, such as artificial intelligence-based diagnostic tools and telemedicine platforms, is transforming the management of dry AMD by enhancing early detection, remote monitoring, and personalized care delivery. These technologies not only improve patient outcomes but also aligns healthcare delivery and expand access to specialized eye care services. Overall, the global dry AMD market presents lucrative opportunities for stakeholders to invest in research, innovation, and collaborative partnerships aimed at addressing the multifaceted challenges posed by this complex disease. By leveraging advancements in technology and therapeutic innovation, the market can drive progress towards more effective treatments, improved diagnostic tools, and enhanced care delivery models, ultimately enhancing outcomes and quality of life for individuals affected by dry AMD.
The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this industry, across different geographies. Amongst other elements, the market report includes:
A preface providing an introduction to the full report, Dry Age-Related Macular Degenerationmarket, 2023-2033.
An outline of the systematic research methodology adopted to conduct the study on Dry Age-Related Macular Degenerationmarket, providing insights on the various assumptions, methodologies, and quality control measures employed to ensure accuracy and reliability of our findings.
An overview of economic factors that impact the overall Dry Age-Related Macular Degenerationmarket, including historical trends, currency fluctuation, foreign exchange impact, recession, and inflation measurement.
An executive summary of the insights captured during our research, offering a high-level view of the current state of the Dry Age-Related Macular Degenerationmarket and its likely evolution in the mid-to-long term.
A brief introduction to the Dry Age-Related Macular Degeneration, highlighting their historical background, as well as information on their types, key aspects, key challenges and the advantages of using Dry Age-Related Macular Degeneration.
A detailed assessment of the market landscape of Dry Age-Related Macular Degenerationthat are either approved or being evaluated in different stages of development, based on several relevant parameters, such as By Stages (Early Age-Related Macular Degeneration, Intermediate Age-Related Macular Degeneration, Late Age-Related Macular Degeneration), By Age Group (Above 75 Years, Above 60 Years, Above 40 Years), By Diagnosis and Treatment (Treatment, Diagnosis), By Route of Administration (Oral, Injectable), By End-User (Hospitals and Clinics, Diagnostic Centers, Academic Research Institutes). Further, the chapter features analysis on key niche market segments. In addition, the chapter features analysis of various Dry Age-Related Macular Degenerationdevelopers, based on their year of establishment, company size, location of headquarters and most active players.
An in-depth analysis of partnerships and collaborations that have been inked between various stakeholders, since 2019, based on several relevant parameters, such as the year of partnership, type of partnership, focus of partnership, purpose of partnership, therapeutic applications and most active players (in terms of number of partnerships). It also highlights the regional distribution of partnership activity in this market.
A detailed analysis of various investments made by companies engaged in this industry, since 2019, based on several relevant parameters, such as year of funding, type of funding (grants, seed, venture capital, initial public offering, secondary offerings, private equity and debt financing), type of HPAPIs, amount invested, geography, purpose of funding, stage of development, therapeutic area, most active players (in terms of number and amount of funding instances) and leading investors (in terms of number of funding instances).
An in-depth analysis of the various Dry Age-Related Macular Degenerationfocused initiatives undertaken by big market players, based on several relevant parameters, such as number of initiatives, year of initiative, type of initiative, purpose of initiative, focus of initiative and location of headquarters of the big pharma players.
One of the key objectives of this market report was to estimate the current market size and the future growth potential of the Dry Age-Related Macular Degenerationover the forecast period. Based on several parameters, such as regional analysis as well as segmental analysis rates, we have developed informed estimates of the likely evolution of the Dry Age-Related Macular Degenerationmarket over the forecast period 2023-2033. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as By Stages (Early Age-Related Macular Degeneration, Intermediate Age-Related Macular Degeneration, Late Age-Related Macular Degeneration), By Age Group (Above 75 Years, Above 60 Years, Above 40 Years), By Diagnosis and Treatment (Treatment, Diagnosis), By Route of Administration (Oral, Injectable), By End-User (Hospitals and Clinics, Diagnostic Centers, Academic Research Institutes), by key geographical regions (North America, Europe, Asia-Pacific, Middle East and Africa, and South America) and leading players. In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s evolution.